Evidence map›Paper›PMID 31721442›Full record

ArticleCurrent protocols in protein science2019

Antibody Panel Based N-Glycan Imaging for N-Glycoprotein Biomarker Discovery.

Alyson P Black, Peggi M Angel, Richard R Drake, Anand S Mehta

Abstract read
In one paragraph

Article in Current protocols in protein science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. High-Throughput Glycomic Methods.Chemical reviews · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Imidazolium labelling permits the sensitive mass-spectrometric detection ofChemical communications (Cambridge, England) · 2021
    Article
  12. Review
  13. Review
  14. Article
  15. Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alyson P BlackDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
Peggi M AngelDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
Richard R DrakeDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.
Anand S MehtaDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina.

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
South Carolina Clinical & Translational Research Institute (SCTR)TL1TR001451 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI FEGHALI-BOSTWICK, CAROL A. · 2015 to 2024
$4.6M
Predicting HCC through GlycomicsR01CA120206 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHTA, ANAND S. · 2006 to 2016
$4.3M
Glycopathology of HCC: identification of the source cells of serum fucosylationU01CA226052 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DRAKE, RICHARD R., HOSHIDA, YUJIN · 2019 to 2023
$2.8M
Simplified Glycan Profiling Workflows of Captured Immune Glycoproteins and CellsU01CA242096 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ANGEL, PEGGI M, DRAKE, RICHARD R. · 2019 to 2021
$818k
Glyco-typer: an antibody capture glycan imaging methodologyR21CA225474 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAAB, BRIAN B., MEHTA, ANAND S. · 2018 to 2019
$731k
NCATS NIH HHS TL1 TR001451NCATS NIH HHS UL1 TR001450NCI NIH HHS R01 CA120206NCI NIH HHS R21 CA225474NCI NIH HHS U01 CA226052NCI NIH HHS U01 CA242096
6 · The paper itself

Abstract

Antibody panel based N-glycan imaging is a novel platform for N-glycan analysis of immunocaptured proteins. N-glycosylation is a post-translational modification of pathophysiological importance and is often studied in the context of disease biomarkers. Determination of protein-specific N-glycosylation changes in patient samples has traditionally been laborious or limited to study of a single protein per analysis. This novel technique allows for the multiplexed analysis of N-glycoproteins from biofluids. Briefly, this platform consists of antibodies spotted in an array panel to a microscope slide, specific capture of glycoproteins from a biological sample, and then enzymatic release of N-glycans for analysis by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS). N-glycans are detected at each individual spot, allowing N-glycan information to easily be linked back to its protein carrier. Using this protocol, multiplexed analysis of N-glycosylation on serum glycoproteins can be performed. Human serum is discussed here, but this method has potential to be applied to other biofluids and to any glycoprotein that can be captured by a validated antibody. © 2019 by John Wiley & Sons, Inc. Basic Protocol: Antibody panel based N-glycan imaging by MALDI MS Support Protocol: Confirmation of antibody capture by IR-labeled proteins.

Indexed as

AntibodiesBiomarkersGlycoproteinsGlycosylationHumansPolysaccharidesProtein Processing, Post-TranslationalSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntibodiesBiomarkersGlycoproteinsPolysaccharidesantibody panelbiomarkermass spectrometry imagingN-glycan

Identifiers

PMID31721442
PMCPMC6859948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.